Raymond James began coverage on shares of Crispr Therapeutics (NASDAQ:CRSP) in a report issued on Thursday, September 20th, Marketbeat.com reports. The firm issued an underperform rating on the stock.
Other analysts have also recently issued research reports about the company. BidaskClub cut Crispr Therapeutics from a buy rating to a hold rating in a research report on Wednesday, June 13th. ValuEngine raised Crispr Therapeutics from a hold rating to a buy rating in a research report on Saturday, June 2nd. Citigroup lowered their price objective on Crispr Therapeutics from $51.00 to $50.00 and set a neutral rating for the company in a research report on Friday, August 24th. Zacks Investment Research lowered Crispr Therapeutics from a hold rating to a sell rating in a research note on Friday, August 10th. Finally, Cann reiterated a hold rating on shares of Crispr Therapeutics in a research note on Monday, September 17th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Crispr Therapeutics currently has a consensus rating of Buy and a consensus price target of $62.47.
NASDAQ:CRSP traded up $0.75 during midday trading on Thursday, hitting $37.70. The stock had a trading volume of 1,644,820 shares, compared to its average volume of 1,240,602. Crispr Therapeutics has a one year low of $16.51 and a one year high of $73.90. The stock has a market cap of $2.09 billion, a P/E ratio of -22.05 and a beta of 3.70.
Several large investors have recently bought and sold shares of CRSP. Rockefeller Capital Management L.P. acquired a new stake in Crispr Therapeutics in the 2nd quarter worth about $116,000. Signaturefd LLC boosted its holdings in Crispr Therapeutics by 123.8% in the 2nd quarter. Signaturefd LLC now owns 2,350 shares of the company’s stock worth $138,000 after buying an additional 1,300 shares during the last quarter. First Mercantile Trust Co. acquired a new stake in Crispr Therapeutics in the 2nd quarter worth about $141,000. SeaCrest Wealth Management LLC boosted its holdings in Crispr Therapeutics by 202.9% in the 2nd quarter. SeaCrest Wealth Management LLC now owns 2,726 shares of the company’s stock worth $160,000 after buying an additional 1,826 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Crispr Therapeutics by 66.3% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,827 shares of the company’s stock worth $166,000 after purchasing an additional 1,127 shares during the last quarter. Hedge funds and other institutional investors own 39.13% of the company’s stock.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.
Featured Story: How Do I Invest in Dividend Stocks
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.